Enabling Cures with Stem Cell Therapies

Who We Are

Jasper is a biotechnology company focused on enabling cures with hematopoietic stem cell therapies.

Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing an improved end-to-end stem cell transplantation process and associated therapies, starting with safer and more effective conditioning agents and engineered stem cell therapies.

Learn More

Our Targeted Conditioning Agent

JSP191 is a targeted CD117 monoclonal antibody conditioning agent designed to enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.

Our initial indication is severe combined immunodeficiency (SCID) for which we are currently conducting a Phase 1/2 study. We also are evaluating JSP191 in a Phase 1 study in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia. Jasper has partnered with academia as well as industry to expand the application of JSP191 to Fanconi anemia with Stanford University, sickle cell disease and chronic granulomatous disease with the NIH and gene therapies with Graphite Bio as well as Aruvant Sciences. Later this year, Jasper plans to initiate a pilot study to evaluate JSP191 in autoimmune diseases, including severe scleroderma, systemic lupus erythematosus and multiple sclerosis.

Learn More

Our Cellular
Engineering Platform

Jasper’s Engineered Hematopoietic Stem Cells (eHSCs) are designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

By using mRNA or DNA editing, Jasper can give the modified donor or autologous stem cells a proliferative and survival advantage (transient or permanent) over the patient’s existing stem cells. Ultimately, our aim is to achieve superior engraftment leading to higher percentages of therapeutic transplants and more effective gene therapies. Furthermore, eHSCs may expand the potential for off the shelf transplants while removing the risk of GVHD and reducing or eliminating the need for toxic conditioning compared to current standard of care therapies.

Learn More

Leadership Team

Jasper Therapeutics’ management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization.

With this leadership, we are well positioned to achieve our vision of increasing cure rates of allogeneic and gene therapy grafts while significantly expanding the eligible patient population.

Learn More

Top